AdvanTIG-206: a phase II, randomized study of ociperlimab plus tislelizumab and BAT1706 (bevacizumab biosimilar) versus tislelizumab and BAT1706 in first-line hepatocellular carcinoma. - Ren Z; Huang Y; Guo Y; Hou MM; Wang W; Kuang M; Hao C; Zhang Y; Song T; Dai C; Kuo HT; Bao Z; et al. (Cancer immunology, immunotherapy : CII, 2026)